Early Detection of Familial Hypercholesterolemia in Children
Recruiting · NCT04370899 · Observational (researchers observe without assigning treatment) · Lead sponsor: Institut Investigacio Sanitaria Pere Virgili
View the official record on ClinicalTrials.gov →Interventions studied
lifestyle assessment
What this trial is about
Heterozigous FH is an underdiagnosed disease in the paediatric population. Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.
Who can take part
Age range
2 Years to 18 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Children between 2 and 18 years of age.
- LDL-C level above 135 mg/dL
- Previously, the pediatrician will have discarded secondary causes (hypercholesterolaemia such as hypothyroidism, nephrotic syndrome, diabetes, renal insufficiency).
- After confirmation that one of the parents has a genetic mutation (Lipoxip/Liponext) or clinical diagnosis (DLCN ≥ 8), the child will be studied. The progenitor with hypercholesterolemia will be considered as an index case, in this way we will demonstrate the vertical transmission of the genetic disease.
Exclusion criteria
- The child population under 2 and over the age of 18 and children.
- Children with high cholesterol but by secondary causes.
Where it is running
2 locations listed.
- Hospital Universitari Sant Joan de Reus - Reus, Tarragona, Spain
- Hospital Universitari Sant Joan - Reus, Tarragona, Spain